Immune Training Device
TECHNOLOGY NUMBER: 2019-005
OVERVIEW
Synthetic hydrogel system supporting ovarian tissue survival and restoring reproductive endocrine function.- Achieves higher functional graft survival and lower rejection rates than traditional controls and commercial immunoisolating devices.
- Restores reproductive endocrine function and puberty or fertility in women and children experiencing premature ovarian failure.
BACKGROUND
The endocrine system relies on interconnected cellular signaling, meaning a loss of function in one gland negatively impacts tissues throughout the body. For example, life-saving cytotoxic chemotherapy treatments frequently lead to premature ovarian failure in pediatric and adult cancer patients. Historical approaches to management present severe shortcomings. Hormone replacement therapy carries health risks linked to non-physiological hormone levels, while tissue cryopreservation followed by auto-transplantation risks re-introducing malignant cells harbored within the stromal tissue. Allo-transplantation of donor ovarian tissue offers a alternative solution, but performing it successfully without chronic immunosuppression remains a major clinical challenge. Primary tissue death from hypoxia and host immune rejection, driven by cellular or humoral pathways, routinely cause allograft failure. Consequently, an urgent need exists for biocompatible systems capable of supporting sustained tissue survival and long-term hormone delivery.
INNOVATION
The proposed technology uses a dual poly(ethylene glycol) synthetic hydrogel system to encapsulate and protect donor ovarian tissue allografts. The device features a semi-permeable membrane structure created by UV-crosslinking a tissue-containing droplet within a protective shell. This design blocks host immune elements such as T cells and antibodies while permitting the diffusion of essential nutrients, oxygen, and hormones including FSH, LH, estrogen, and progesterone. Antigens shed from the graft diffuse slowly through the non-degradable shell, inducing host immune tolerance without sensitization. In ovariectomized animal models, the device supports folliculogenesis with minimal capsule fibrosis and restores normal estrous cycling and serum hormone levels. Real-world applications focus on restoring endocrine function, puberty, and fertility in patients suffering from premature ovarian failure caused by chemotherapy.
ADDITIONAL INFORMATION
REFERENCES
Day, J. R., David, A., Cichon, A. L., Kulkarni, T., Cascalho, M., & Shikanov, A. (2018). Immunoisolating poly(ethylene-glycol) based capsules support ovarian tissue survival to restore endocrine function. Journal of Biomedical Materials Research Part A, 106(5), 1381–1389. https://doi.org/10.1002/jbm.a.36338
INTELLECTUAL PROPERTY
Patent Pending
RELATED TECHNOLOGY
- Restoration of Ovarian Endocrine Function
- Device for the subcutaneous administration of pre-polymerized hydrogels
- Immune Isolating Device With Improved Diffusion
- Method for analysis and selection of human ovarian tissue for grafting in an immune-isolating capsule
- Multi-Fractional Immunoisolating Device for Human Ovarian Tissue